Funding for this research was provided by:
Received: 17 December 2019
Accepted: 12 April 2020
First Online: 29 May 2020
Ethics approval and consent to participate
: The study protocol, any amendments, the informed consent, and other information that required pre-approval were reviewed and approved by a national, regional, or investigational site ethics committee or institutional review board (IRB), in accordance with the International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice and applicable country-specific requirements. All study patients provided written informed consent.
: Not applicable.
: N Brown, C Compton, TC Corbridge, K Dorais, C Harvey, MC Kaisermann, DA Lipson, N Martin, M Stiegler, and C-Q Zhu are employees of GlaxoSmithKline (GSK) and are shareholders in GSK. GT Ferguson received grants, personal fees, and non-financial support from Boehringer Ingelheim, Novartis, AstraZeneca, Pearl Therapeutics, Sunovion, Theravance, and GSK, grants and personal fees from Verona, and Sanofi, and personal fees from Mylan, Innoviva, and Circassia, and grants from Altavant, unrelated to this work. C Fogarty has nothing to disclose. F Sciurba received research support from the COPD Foundation, Department of Defense Beta Blocker, Gala Therapeutics, Inc., GSK, NIH, Nuvaira, PCORI, PneumRX, Inc., PulmonX, and ResMed Corp, participated in advisory board for GSK, PneumRX, Inc., Theravance, and Verona and previously received research support from Astellas and AstraZeneca, unrelated to this work. D Bernstein has received grants and personal fees from GSK and ALK America, grants from Aimmune, Amgen, AstraZeneca, Genentech, Merck, Mylan, Novartis, Pearl, Shire, Teva, Adare, Knopp, Leo, Mandala, Gossamer, and Regeneron, and personal fees from Gerson Lehman, Guidepoint Global, and Covis, unrelated to this work.